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considering that 45% of the study patients had inef- (Global Registry of Acute Coronary Events) score and treatment effect (e.g., 16% of higher-risk patients had harm, whereas lower-risk patients had a benefit).
Notwithstanding, a patient with a lower GRACE score but with a residual significant stenosis of the infarctrelated artery supplying a large territory of viable myocardium might be the one who benefits most from a successful very early PCI. On the contrary, in the older patient with renal dysfunction, diabetes, and patent infarct-related artery with residual moderate lesion, even a successful PCI cannot change the intrinsic high-risk profile according to GRACE score.
Accordingly, by multivariate analysis, Madan et al. (9) found that the prediction model of early and late adverse outcome was almost entirely grounded in clinical variables included in the Thrombolysis In
Myocardial Infarction risk score, and that these are generally irreversible risk factors despite successful PCI. Nevertheless, in these high-risk patients, adjunctive PCI to lytic might still provide a benefit in terms of recurrent ischemic events, not necessarily related to the infarct related artery.
A further argument of discussion is whether a very early invasive strategy (<2 h), as proposed by the authors, should be differentiated from facilitated PCI.
Besides the lower platelet inhibition in the facilitated PCI studies, a major difference seems to be that trials In conclusion, we are indebted to the authors for providing us with more evidence that a pharmacoinvasive approach without time delay to perform angiography and PCI (if appropriate) might be the way to go. Nevertheless, considering that primary PCI, if available, is better than facilitated PCI, the extra mile is to identify specific barriers to the implementation of guidelines and to define actions to ensure that the majority of STEMI patients have access to the lifesaving optimal reperfusion therapy (i.e., primary PCI). This is the mission of the ambitious European initiative of "Stent for Life" (19) . 
